2022 World Conference on Lung Cancer (ePosters)-EP03.01-003. Clinical Features and Molecular Profile of Advanced Non-small Cell Lung Cancer in Latin America: LATINO Lung (LACOG 0116)

EP03.01-003. Clinical Features and Molecular Profile of Advanced Non-small Cell Lung Cancer in Latin America: LATINO Lung (LACOG 0116)

Back to course

Pdf Summary

The LATINO Lung study is an observational study conducted in Latin America to understand the characteristics and diagnostic profiles of patients with advanced non-small cell lung cancer (NSCLC) in the region. The study aims to address the challenges in delivering optimal care for NSCLC in Latin America, including delay in diagnosis, limited access to biomarker testing, and restricted availability of novel therapies.<br /><br />The study included 727 patients from four countries in Latin America: Argentina, Brazil, Colombia, and Mexico. The majority of patients were from Brazil (82.1%). The median time from the first symptom to diagnostic biopsy was 3.3 months, highlighting a delay in the diagnosis process. The most common first symptoms reported by patients were cough, chest pain, dyspnea, and weight loss.<br /><br />The majority of patients had a smoking history (69.3%), but interestingly, 30% of patients were non-smokers, which is higher than in other regions. Adenocarcinoma was the most frequent histology observed in these patients. Molecular testing was performed in 80% of adenocarcinoma cases, with a significant prevalence of EGFR mutation and ALK-positive tumors.<br /><br />The study also assessed the expression of PD-L1, a biomarker that helps identify patients who may benefit from immunotherapy. PD-L1 testing was performed in 50.4% of patients, and the results were consistent with other reports. Among patients with adenocarcinoma, 79.5% had molecular testing, with a high prevalence of EGFR mutation (39.3%) and ALK-positive tumors (12.1%).<br /><br />Overall, the LATINO Lung study provides valuable real-world data on the clinical features and molecular profile of advanced NSCLC in Latin America. This information will be instrumental in improving clinical management and informing public health policies in the region. The study was funded by BMS and Pfizer, and the data analysis was performed using Statistical Analysis Software (SAS).

Asset Subtitle

Clarissa Mathias

Meta Tag

Speaker Clarissa Mathias

Topic Epidemiology

Keywords

LATINO Lung study

observational study

Latin America

non-small cell lung cancer

diagnostic profiles

delay in diagnosis

molecular testing

EGFR mutation

ALK-positive tumors

PD-L1 testing